Clinical Trials Logo

Lysosomal Storage Disease clinical trials

View clinical trials related to Lysosomal Storage Disease.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03392987 Active, not recruiting - Clinical trials for Metachromatic Leukodystrophy

A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (MLD)

Start date: January 25, 2018
Phase: Phase 2
Study type: Interventional

OTL-200 is autologous CD34+ cells transduced with lentiviral vector containing human arylsulfatase A (ARSA) complementary deoxyribonucleic acid (cDNA) used for the treatment of MLD. MLD is an autosomal recessive lysosomal storage disorder (LSD) characterized by severe and progressive demyelination affecting the central and peripheral nervous system. This study will assess safety and efficacy of treatment using cryopreserved formulation of OTL-200 in pediatric subjects with pre-symptomatic Early Onset MLD (Late Infantile (LI) to Early Juvenile (EJ) MLD) and early symptomatic EJ MLD.

NCT ID: NCT01560182 Active, not recruiting - Clinical trials for Metachromatic Leukodystrophy

Gene Therapy for Metachromatic Leukodystrophy (MLD)

Start date: April 9, 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This Phase I/II clinical trial consists of the application of lentiviral vector-based gene therapy to patients affected by Metachromatic Leukodystrophy (MLD), a rare inherited Lysosomal Storage Disorder (LSD) resulting from mutations in the gene encoding the Arylsulfatase A (ARSA) enzyme. The medicinal product consists of autologous CD34+ hematopoietic stem/progenitor cells in which a functional ARSA cDNA is introduced by means of 3rd generation VSV-G pseudotyped lentiviral vectors.